@article{c05361fbe1484624bd89c8df54191d37,
title = "Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group",
abstract = "Introduction: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. Methods: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents. Results: Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice. Discussion: This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.",
keywords = "clinical trials, medical oncology, nuclear medicine, prostate-specific membrane antigen (PSMA), radiation therapy, radiology, radionuclides, radiopharmaceuticals, urology",
author = "Miyahira, {Andrea K.} and Pienta, {Kenneth J.} and Morris, {Michael J.} and Bander, {Neil H.} and Baum, {Richard P.} and Fendler, {Wolfgang P.} and William Goeckeler and Gorin, {Michael A.} and Hartwig Hennekes and Pomper, {Martin G.} and Oliver Sartor and Tagawa, {Scott T.} and Scott Williams and Soule, {Howard R.}",
note = "Funding Information: K.J.P. and M.A.G. have received research support from Progenics Pharmaceuticals. M.J.M. is an uncompensated consultant to Endocyte, Progenics and Bayer, is a consultant to Advanced Accelerator Applications (AAA) and Blue Earth Diagnostics, and has received research funding through Memorial Sloan Kettering Cancer Center from Endocyte, Progenics and Bayer. N.H.B. is an inventor on patents that are assigned to Cornell Research Foundation (CRF) for the J591 antibody. N.H.B. is a consultant to and owns stock in BZL Biologics, the company to which the patents were licensed by CRF for further research and development. R.P.B. has served as consultant, advisor, and/or received honoraria from AAA, IPSEN Pharma, ITG Isotope Technologies Garching (ITG), and Telix Pharmaceuticals, and has received grant or research support from AAA and ITG. W.P.F. is an uncompensated consultant for Endocyte, and a consultant for Ipsen. W.-G. is an employee of Bayer Healthcare LLC., USA. H.H. is an employee and shareholder of Bayer AG, Germany. M.G.P. has licensed technology to and received research funding from Progenics Pharmaceuticals and AAA. O.S. has served as a consultant to Endocyte and AAA. S.T.T. has served as a consultant to Bayer and Endocyte and Weill Cornell Medicine has received research funding on his behalf for clinical trials from Bayer and Endocyte. S.W. has received travel support from and has served as an uncompensated consultant to Astellas. Funding Information: We thank Bayer Healthcare for the generous unrestricted support of this meeting. We also acknowledge the meeting planning efforts of Carla Appling (PCF) and Cynthia Lendor (Weill Cornell Medicine). Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = aug,
day = "1",
doi = "10.1002/pros.23642",
language = "English (US)",
volume = "78",
pages = "775--789",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "11",
}